Covid-19 Tedavisinde Kullanılan İlaçlar ve İlaç Etkileşimleri

Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58.

Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. Journal of Heart and Lung Transplantation. 2020; 39(5):405-407.

Nursel S, Kutay D. COVID-19 Tedavisinde Kullanılan İlaçlar ve Akılcı İlaç Kullanımı. Arch Med Rev J. 2020;29:44–53.

Jafari A, Dadkhahfar S, Perseh S. Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments. Crit Rev Oncol Hematol. 2020;151:102982.

Zhang L, Zhang Y, Zhao P, Huang SM. Predicting drug-drug interactions: An FDA perspective. AAPS J. 2009;11(2):300-306.

Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13(1):74.

Jagadeesan M, Manikandan R, Sudha NSS. The Drug-Drug Interactions: Affecting the Rationality of Prescriptions. Res J Pharm Technol. 2018;11(7):3077.

T.C Sağlık Bakanlığı COVID-19 Bilgilendirme Sayfası (2020). COVID-19 Rehberi, Erişkin Hasta Tedavisi. (20/01/2021 tarihinde https://covid19.saglik.gov.tr/TR-66301/covid-19-rehberi.html adresinden ulaşılmıştır).

T.C Sağlık Bakanlığı COVID-19 Bilgilendirme Sayfası (2020). COVID-19 Rehberi, Antisitokin-Antiinflamatuar Tedaviler, Koagülopati Yönetimi. (20/01/2021 tarihinde https://covid19.saglik.gov.tr/TR-66301/covid-19-rehberi.html adresinden ulaşılmıştır).

Verbaanderd C, Maes H, Schaaf MB, Sukhatme VP, Pantziarka P, Sukhatme V, et al. Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents. Ecancermedicalscience. 2017;11.

Solomon VR, Lee H. Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies. European Journal of Pharmacology. 2009;625:220-233.

Wu R, Wang L, Kuo H-CD, Shannar A, Peter R, Chou PJ, et al. An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Reports. 2020;6(3):56–70

Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK. Drug repurposing approach to fight COVID-19. Pharmacol Reports. 2020;72(6):1479–508.

Repurposed Antiviral Drugs for Covid-19 Interim WHO Solidarity Trial Results. N Engl J Med. 2020 ;NEJMoa2023184.

University of Liverpool COVID-19 drug interactions (2021). Detailed recommendations for interactions with experimental COVID-19 antiviral therapies. (5/02/2021 tarihinde https://www.covid19-druginteractions.org/prescribing-resources adresinden ulaşlmıştır)

Marra F, Smolders EJ, El-Sherif O, Boyle A, Davidson K, Sommerville AJ, et al. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. Drugs R D. 2020;1–19.

Li X, Wang Y, Agostinis P, Rabson A, Melino G, Carafoli E, et al. Is hydroxychloroquine beneficial for COVID-19 patients? Cell Death Dis. 2020;11(7):512.

METBULUT P, DİBEK MISIRLIOĞLU E. Adverse Drug Reactions During COVID-19 Treatment. Turkish J Pediatr Dis. 2020;65–71.

Al-Zidan RN. Potential Drug-Drug and Drug-Disease interactions of selected experimental therapies used in treating COVID-19 patients. J Drug Deliv Ther. 2020;10(6):219–30.

T.C Sağlık Bakanlığı COVID-19 Bilgilendirme Sayfası (2020). COVID-19 (Sars-Cov2 Enfeksiyonu) Tedavı̇sinde Kullanılacak İlaçlara İlı̇şkı̇n Bı̇lgı̇lendı̇rme (Hı̇droksı̇klorokı̇n Sülfat 200 mg Film Tablet). (20/01/2021 tarihinde https://covid19.saglik.gov.tr/TR-66535/covid-19-sars-cov2-enfeksiyonu-tedavisinde-kullanilacak-ilaclara-iliskin bilgilendirme-hidroksiklorokin-sulfat-200-mg-film-tablet.html adresinden ulaşılmıştır).

Gilbert, D. N., Chambers, H. F., & Eliopoulos GM. The Sanford Guide to Antimicrobial Therapy 2020. 50th ed. 2020. 304 p.

Potì F, Pozzoli C, Adami M, Poli E, Costa LG. Treatments for COVID-19: emerging drugs against the coronavirus. Acta Biomed. 2020;91(2):118–36.

Alhajj S, Gencer S. Investigating Side Effects of Existing Drugs Used in Covid-19 Treatment. In 2020.

Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854–87.

Lemaitre F, Solas C, Grégoire M, Lagarce L, Elens L, Polard E, et al. Potential drug–drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Fundamental and Clinical Pharmacology. 2020;34(5):530-547.

Faizah AK, Nurrahman NWD, Putra ON. A Mini Review : Clinically Significant Potential Drug-Drug Interactions In COVID-19 and Comorbid Therapy. Pharm Sci Res. 2020;7(4):23–8.

UpToDate (2020). Favipiravir (United States: Not commercially available; refer to Prescribing and Access Restrictions): Drug information. (20/01/2021 tarihinde https://www.uptodate.com/contents/favipiravir-united-states-not-commercially-available-refer-to-prescribing-and-access-restrictions-druginformation?search=favipiravir&topicRef=127429&source=see_link adresinden ulaşılmıştır).

Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. American Journal of Emergency Medicine. 2020;38(7):1488-1493.

Bolarin JA, Oluwatoyosi MA, Orege JI, Ayeni EA, Ibrahim YA, Adeyemi SB, et al. Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective. Int Immunopharmacol. 2021;90:107228.

U.S.Food&Drug Administration (FDA) (2020).Highlights of Presciribing Information-Veklury. (20/01/2021 tarihinde https://search.usa.gov/search?affiliate=fda1&page=2& query=veklury adresinden ulaşılmıştır).

U.S. Food&Drug Administration (FDA) (2020). Drugs@FDA: FDA-Approved Drugs (Actemra). (20/01/2021 tarihinde https://www.accessdata.fda.gov/drugsatfda_docs/label/ 2020/125276s129,125472s042lbl.pdf adresinden ulaşılmıştır).

Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020; 117(20):10970-10975.

Randomized Evaluation of COVID-19 Therapy (2020). Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. (20/01/2021 Tarihinde https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19 adresinden ulaşılmıştır).

World Health Organization (WHO) (2020). WHO updates clinical care guidance with corticosteroid recommendations. (20/01/2021 tarihinde https://www.who.int/news-room/feature-stories/detail/who-updates-clinical-care-guidance-with-corticosteroid-recommendations adresinden ulaşılmıştır).

UpToDate (2020). Dexamethasone (systemic): Drug information. (20/01/2021 tarihinde https://www.uptodate.com/contents/dexamethasone-systemic-drug-information?search =cov%C4%B1d-19&topicRef=9334&source=see_link adresinden ulaşılmıştır).

Shokr M, Rashed A, Lata K, Kondur A. Dexamethasone Associated ST Elevation Myocardial Infarction Four Days after an Unremarkable Coronary Angiogram—Another Reason for Cautious Use of Steroids: A Case Report and Review of the Literature. Case Reports Cardiol. 2016;2016:1–6.

UpToDate (2020). Coronavirus disease 2019 (COVID-19): Convalescent plasma and hyperimmune globulin. (20/01/2021 tarihinde https://www.uptodate.com/contents/ coronavirus-disease-2019-covid-19-convalescent-plasma-and-hyperimmune globulin ? search= adresinden ulaşılmıştır).

Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016 Mar;14(2):152–7.

Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. Am J Pathol. 2020;190(11):2290-2303.

T.C Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü (2020). COVID-19 İmmün (Kovalesan) Plazma Tedarik ve Klinik Kullanım Rehberi. (20/01/2021 tarihinde https://shgm.saglik.gov.tr/TR-45986/rehberler.html adresinden ulaşılmıştır).

Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al. Safety Update. Mayo Clin Proc. 2020;95(9):1888–97.

Wang Y, Zhang Y, Yu Q, Zhu K. Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on the Newly Established Guidelines for COVID-19 Remedy. Front Pharmacol. 2020;11.

University of Liverpool COVID-19 drug interactions (2021). Detailed recommendations for interactions with experimental COVID-19 immune therapies. (5/02/2021 tarihinde https://www.covid19-druginteractions.org/prescribing-resources adresinden ulaşlmıştır)

T.C Sağlık Bakanlığı COVID-19 Bilgilendirme Sayfası (2020). COVID-19 Tedavisinde Kullanılan İlaçlar – İlaç Etkileşimler. (08/02/2021 tarihinde https://covid19.saglik .gov.tr/TR-66541/covid-19-tedavisinde-kullanilan-ilaclar---ilac-etkilesimleri.html adresinden ulaşılmıştır).